MX2017000082A - Composiciones y metodos para mejorar terapias con celulas adoptivas. - Google Patents

Composiciones y metodos para mejorar terapias con celulas adoptivas.

Info

Publication number
MX2017000082A
MX2017000082A MX2017000082A MX2017000082A MX2017000082A MX 2017000082 A MX2017000082 A MX 2017000082A MX 2017000082 A MX2017000082 A MX 2017000082A MX 2017000082 A MX2017000082 A MX 2017000082A MX 2017000082 A MX2017000082 A MX 2017000082A
Authority
MX
Mexico
Prior art keywords
methods
compositions
stabilizers
agonists
cells
Prior art date
Application number
MX2017000082A
Other languages
English (en)
Inventor
K Marathi Upendra
Original Assignee
7 Hills Interests Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 7 Hills Interests Llc filed Critical 7 Hills Interests Llc
Publication of MX2017000082A publication Critical patent/MX2017000082A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen composiciones y métodos para mejorar la potencia y eficacia de una terapia con células adoptivas al utilizar estabilizadores con ligandos de integrina, en donde la integrina se selecciona del grupo que consiste de a4ß1, a5ß1, a4ß7, avß3 y aLß2, y poner en contacto las células efectoras ex vivo con agonistas o estabilizadores que tengan la Fórmula general (I); los métodos para tratar células que expresan integrinas con estos estabilizadores para mejorar la infiltración tumoral; y los métodos terapéuticos que comprenden administrar un estabilizador o células tratadas con agonistas a un mamífero que requiera del tratamiento de tumores sólidos, cánceres hematológicos.
MX2017000082A 2014-07-01 2015-06-30 Composiciones y metodos para mejorar terapias con celulas adoptivas. MX2017000082A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462019793P 2014-07-01 2014-07-01
PCT/US2015/038447 WO2016003980A1 (en) 2014-07-01 2015-06-30 Compositions and methods to improve adoptive cell therapies

Publications (1)

Publication Number Publication Date
MX2017000082A true MX2017000082A (es) 2017-05-30

Family

ID=55016230

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000082A MX2017000082A (es) 2014-07-01 2015-06-30 Composiciones y metodos para mejorar terapias con celulas adoptivas.

Country Status (8)

Country Link
US (2) US11484524B2 (es)
EP (1) EP3164127A4 (es)
JP (1) JP2017521435A (es)
CN (1) CN106604727A (es)
AU (2) AU2015284263B2 (es)
CA (1) CA2954175C (es)
MX (1) MX2017000082A (es)
WO (1) WO2016003980A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2954175C (en) 2014-07-01 2023-07-25 Upendra K. Marathi Compositions and methods to improve adoptive cell therapies
KR20240052078A (ko) 2015-04-29 2024-04-22 7 힐즈 인터레스츠 엘엘씨 소분자 인테그린 수용체-리간드 작용제 보강제를 포함하는 면역치료를 위한 새로운 조성물과 방법
US11311619B2 (en) 2016-04-28 2022-04-26 7 Hills Pharma Inc. and Texas Heart Institute Integrin activator vaccine compositions
US20180184610A1 (en) * 2018-01-31 2018-07-05 Nunhems B.V. Spinach variety nun 06303 sps

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL343770A1 (en) 1998-04-16 2001-09-10 Texas Biotechnology Corp N,n-disubstituted amides that inhibit the binding of integrins to their receptors
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
KR101000358B1 (ko) * 2010-04-29 2010-12-13 서울대학교산학협력단 인테그린 αⅤβ３ 결합성 지질 유도체 및 그를 포함하는 지질 나노입자
ES2677668T3 (es) * 2010-11-16 2018-08-06 Texas Heart Institute Agonistas que mejoran la unión de células que expresan integrina a receptores de integrina
AU2015217142B2 (en) 2014-02-12 2020-04-09 7 Hills Pharma LLC Compositions and methods to improve the homing and grafting of hematopoetic stem cells
CA2954175C (en) 2014-07-01 2023-07-25 Upendra K. Marathi Compositions and methods to improve adoptive cell therapies

Also Published As

Publication number Publication date
AU2015284263A1 (en) 2017-02-02
US20160000755A1 (en) 2016-01-07
CA2954175C (en) 2023-07-25
AU2021202260A1 (en) 2021-05-06
US20210145796A1 (en) 2021-05-20
CN106604727A (zh) 2017-04-26
WO2016003980A1 (en) 2016-01-07
AU2015284263B2 (en) 2021-02-25
JP2017521435A (ja) 2017-08-03
EP3164127A1 (en) 2017-05-10
CA2954175A1 (en) 2016-01-07
EP3164127A4 (en) 2017-11-22
AU2021202260B2 (en) 2022-11-10
US11484524B2 (en) 2022-11-01

Similar Documents

Publication Publication Date Title
EA201201186A1 (ru) ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
JOP20180104B1 (ar) مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
MX2016008201A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
EA201290901A1 (ru) Фитоканнабиноиды для лечения злокачественной опухоли
MX2017016868A (es) Composiciones y metods para inhibir actividad de arginasa.
ECSP18094983A (es) Derivados de pirazol como inhibidores de la calicreína plasmática
CO2017011197A2 (es) Terapia de combinación fgfr/pd-1 para el tratamiento del cancer
CY1119676T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια του καρκινου
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
EP4272757A3 (en) Modified nk-92 cells for treating cancer
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
EA201791094A1 (ru) Аналоги простых эфиров фосфолипидов в качестве носителей лекарственных средств, нацеленных на раковые клетки
EA201691079A1 (ru) Комбинированная терапия для лечения онкологического заболевания
EA201890009A1 (ru) Ингибиторы ezh2 для лечения лимфомы
ECSP15042895A (es) Compuestos de biaril-amida como inhibidores de cinasa
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
EA201591543A1 (ru) Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
MX2016015436A (es) Compuestos para tratar el cancer cerebral.
EA201591925A1 (ru) Терапевтические композиции и их применение
MX2015013784A (es) C. novyi para el tratamiento de tumores solidos en humanos.
MX2017000082A (es) Composiciones y metodos para mejorar terapias con celulas adoptivas.
MX2017011018A (es) Inhibicion de la actividad de olig2.